Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2973362 | 0.99 | HTR4 (0.62) | HTR4 | |
| SCHEMBL2334767 | 0.85 | HTR4 (0.60) | HTR4 | |
| SCHEMBL2334166 | 0.84 | HTR4 (0.61) | HTR4 | |
| SCHEMBL2336956 | 0.84 | HTR4 (0.57) | HTR4 | |
| Hydrochloric Acid SCHEMBL3295804 | 0.83 | HTR4 (0.60) | HTR4 | |
| SCHEMBL2337607 | 0.83 | HTR4 (0.58) | HTR4 | |
| SCHEMBL2335431 | 0.83 | HTR4 (0.58) | HTR4 | |
| SCHEMBL3299419 | 0.82 | HTR4 (0.55) | HTR4 | |
| SCHEMBL2340631 | 0.82 | HTR4 (0.57) | HTR4 | |
| Hydrochloric Acid SCHEMBL3299088 | 0.82 | HTR4 (0.57) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664036-B1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2011-12-28 | — | — | EP | claimed |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | PFIZER INC. (US) | 2010-10-28 | — | — | US | claimed |
| US-7776885-B2 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER, INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER INC. | 2005-07-07 | — | — | US | claimed |
| EP-1664036-B1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | PFIZER INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7776885-B2 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1664036-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | Pfizer, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005021539-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | HTR4, GPR4, HTR5A | HTR4 1/4885 |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | HTR4, GPR4, HTR5A | HTR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.